Effect of biologic agents on radiographic progression of rheumatoid arthritis

Reports in Medical Imaging

Volumn 3, Issue 1, 2010, Pages 35-44

  Tobón, Gabriel J ^a   Saraux, Alain ^a,b   Devauchelle Pensec, Valérie ^a,b  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Biologics; Radiographic progression; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; BIOLOGIC FACTORS AND AGENTS ACTING ON THE IMMUNE SYSTEM; CD20 ANTIBODY; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 6 ANTIBODY; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

BIOLOGICAL THERAPY; BONE EROSION; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG RESPONSE; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; JOINT RADIOGRAPHY; OUTCOME ASSESSMENT; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

EID: 78649800040     PISSN: None     EISSN: 11791586     Source Type: Journal    
DOI: 10.2147/RMI.S4665     Document Type: Review

References (39)

1. Guillemin F, Saraux A, Guggenbuhl P, et al. Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis. 2005;64(10):1427-1430.
2. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373(9664):659-672.
3. Haraoui B. Assessment and management of rheumatoid arthritis. J Rheumatol Suppl. 2009;82:2-10.
4. Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19 years study of radiographic progression. Arthritis Rheum. 1998;41(9):1571-1582.
5. Hulsmans HM, Jacobs JW, van der Heijde DM, et al. The course of radiologic damage during the six years of rheumatoid arthritis. Arthritis Rheum. 2000;43(9):1927-1940.
6. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11 Suppl 1:S1.
7. Devauchelle-Pensec V, Josseaume T, Samjee I, Dougados M, Combe B, Saraux A. Ability of oblique foot radiographs to detect erosions in early arthritis: results in the ESPOIR cohort. Arthritis Rheum. 2008;59(12):1729-1734.
8. Baron G, Boutron I, Giraudeau B, Ravaud P. Reporting of radiographic methods in randomized controlled trials assessing structural outcomes in rheumatoid arthritis. Ann Rheum Dis. 2007;66(5):651-657.
9. Boini S, Guillemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis. 2001;60(9):817-827.
10. van der Heijde DM. How to read radiographs according to the Sharp/ van der Heijde Method. J Rheumatol. 2000;27:261-263.
11. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum. 1971;14(6):706-720.
12. van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol. 1995;34 Suppl 2:74-78.
13. Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, Countryman PJ. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum. 1998;41(9):1583-1590.
14. Drossaers-Bakker KW, Zwinderman AH, Vliet Vlieland TP, et al. Longterm outcome in rheumatoid arthritis: A simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum. 2002;47(4):383-390.
15. van der Heijde DM, Boonen A, Boers M, et al. Reading radiographs in chronological order, in pairs or as single films has important implications for the discriminative power of rheumatoid arthritis clinical trials. Rheumatology (Oxford). 1999;38(12):1213-1220.
16. Devauchelle-Pensec V, Berthelot JM, Jousse S, et al. Performance of hand radiographs in predicting the diagnosis in patients with early arthritis. J Rheumatol. 2006 33(8):1511-1515.
17. Guillemin F, Billot L, Boini S, Gerard N, Ødegaard S, Kvien TK. Reproducibility and sensitivity to change of 5 methods for scoring hand radiographic damage in patients with rheumatoid arthritis. J Rheumatol. 2005;32(5):778-786.
18. Combe B, Benessiano J, Berenbaum F, et al. The ESPOIR cohort: A ten-year follow-up of early arthritis in France: Methodology and baseline characteristics of the 813 included patients. Joint Bone Spine. 2007;74(5):440-445.
19. Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):578-582.
20. van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate alone and combined in the treatment of rheumatoid arthritis: two year clinical and radiographic results from the TEMPO study, a double blind, randomized trial. Arthritis Rheum. 2006;54(4):1063-1074.
21. Lukas C, van der Heijde D, Fatenejad S, Landewé R. Repair of erosions occurs almost exclusively in damaged joints without swelling. Ann Rheum Dis. 2010;69(5):851-855.
22. Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008;67(10):1360-1364.
23. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861-1874.
24. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004;363(9410):675-681.
25. Smolen JS, van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006;54(3):702-710.
26. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005;52(4):1020-1030.
27. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46(6):1443-1450.
28. van der Heijde D, Landewé R, van Vollenhoven R, Fatenejad S, Klareskog L. Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. Ann Rheum Dis. 2008;67(9):1267-1270.
29. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26-37.
30. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793-2806.
31. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817-2829.
32. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516-1523.
33. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162-1167.
34. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144(12):865-876.
35. Smolen JS, van der Heijde DM, Aletaha D, et al. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. Ann Rheum Dis. 2009;68(10):1535-1540.
36. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586-1593.
37. Genovese MC, Bathon JM, Fleischmann RM, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol. 2005;32(7):1232-1242.
38. Grigor C, Capell H, Stirling A, et al. Effect of the treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single blind randomised controlled study. Lancet. 2004;364(9430):263-269.
39. Vastesaeger N, Xu S, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology. 2009;48(9):1114-1121.